dr. tyna moore glp-1 GLP-1s can change your life... BUT only if you use them correctly. ⠀ In this episode of Between Two Lips, @drtyna explains why many people stall out on GLP-1s Dr Tyna Moore on the

These effects are generally mild and temporary

The increases in NO reported after 28 d GPLC at 4.5 g/d are apparently associated with the extreme leg pump that limited cycling power in the present study

GLP1s that are FDA-approved for the treatment of obesity require prior authorization

This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD [chronic kidney disease], said lead author Sunil Badve, professorial fellow at The George Institute for Global Health and UNSW Sydney

10.3390/ijms19113435 30 GherardiE.BirchmeierW.BirchmeierC.Vande WoudeG